KTE-X19

KTE-X19

Contact

 If you are interested in participating in the study or want to learn more, please get in touch. Contact us
This study is now recruiting. Learn more about enrolling here.

Description

Patients with no available curative treatment options with leukemia are eligible to participate in this study to test an experimental approach called gene transfer that involves B cells. This study will take the patients white blood cells - T cells - and change them to turn against the cancer.

Eligibility and criteria
IRB Number:
16-013488
Eligible age range:
1 years - 21 years
Clinical trial phase:
Phase I
Phase II
Official title:
A PHASE 1/2 MULTI-CENTER STUDY EVALUATING THE SAFETY AND EFFICACY OF KTE-X19 IN PEDIATRIC AND ADOLESCENT SUBJECTS WITH RELAPSED/REFRACTORY B-PRECURSOR ACUTE LYMPHOBLASTIC LEUKEMIA or Relapsed/Refractory B Cell Non Hodgkin Lymphoma (ZUMA-4)
Smiling CHOP patient holding shopping bag

We need families like you

Your time and participation make a difference in supporting the work of the Research Institute and children in our community. Learn more about opportunities to participate in our research.